Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Quest Diagnostics Incorporated DGX

• Quest Diagnostics posted Q1 FY23 adjusted EPS of $2.04, down 36.6% Y/Y, beating the consensus of $1.97. The company’s stock has a 52-week low of $120.40 .
• RSI Value: 28.46
• DGX Price Action: Shares of Quest Diagnostics fell 0.9% to close at $132.43 on Wednesday.

Accolade, Inc. ACCD

• Accolade reported worse-than-expected Q4 sales results. “Fiscal year 2023 marked a transformational time for Accolade, as we tightly integrated our acquisitions, greatly expanded our presence across the healthcare ecosystem, and delivered against our financial objectives,” said Rajeev Singh, Accolade Chief Executive Officer. The company’s stock has a 52-week low of $5.07.
• RSI Value: 29.18
• ACCD Price Action: Shares of Accolade fell 0.8% to close at $10.93 on Wednesday.

Sangamo Therapeutics, Inc. SGMO

• Sangamo Therapeutics said it sees Q1 revenue of $158 million. “This quarter, Sangamo continued to advance its clinical and pre-clinical pipeline. Our Phase 1/2 Fabry study continues to enroll and dose patients, alongside preparations for a potential Phase 3 trial expected to commence by the end of 2023,” said Sandy Macrae, Chief Executive Officer of Sangamo. The company’s stock has a 52-week low of $1.18.
• RSI Value: 29.21
• SGMO Price Action: Shares of Sangamo Therapeutics fell 0.8% to close at $1.27 on Wednesday.

Sotera Health Company SHC

• Sotera Health posted downbeat quarterly results. “As we outlined in our fourth-quarter 2022 earnings call, our first-quarter total revenue was below the same quarter last year, driven by the anticipated timing of Nordion Cobalt-60 harvest schedules and lower volumes for the Nelson Labs and Sterigenics businesses, which is typical for the first quarter of the year,” said Chairman and Chief Executive Officer, Michael B. Petras, Jr. The company’s 52-week low is $5.78.
• RSI Value: 24.95
• SHC Price Action: Shares of Sotera Health fell 0.3% to close at $14.66 on Wednesday.

Bio-Rad Laboratories, Inc. BIO

• Bio-Rad Laboratories reported worse-than-expected Q1 financial results. "The expected decline in first quarter COVID-related sales resulted in lower year-over-year total revenues; however, we are encouraged by continued underlying strength of our core business in Life Science and Clinical Diagnostics," said Norman Schwartz, Bio-Rad’s President and Chief Executive Officer. The company has a 52-week low of $344.63.
• RSI Value: 23.89
• BIO Price Action: Shares of Bio-Rad Laboratories fell 0.3% to close at $365.69 on Wednesday.

Read More: Investor Sentiment Declines Slightly Following Inflation Data